Elite in Dowling-Meara Epidermolysis Bullosa Simplex

Dr. Joyce Teng

Dermatology | Pediatrics
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 
 (2390.7 mi)
Elite in Dowling-Meara Epidermolysis Bullosa Simplex
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 
 (2390.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Joyce Teng is a Dermatologist and a Pediatrics provider in Palo Alto, California. Dr. Teng and is rated as an Elite provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Liver Embolization.

Her clinical research consists of co-authoring 101 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles and participated in 3 clinical trials in the study of Dowling-Meara Epidermolysis Bullosa Simplex.

Specialties
Dermatology
Pediatrics
Licenses
Dermatology in CA
Hospital Affiliations
Lucile Salter Packard Children's Hsp At Stanford
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

LPCH MEDICAL GROUP DIV OF LUCILE
725 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Teng has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Enrollment Status: Available
Publish Date: October 28, 2024
Intervention Type: Drug
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Completed
Publish Date: September 11, 2023
Intervention Type: Drug
Study Drug: TolaSure
Study Phase: Phase 1
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Vehicle
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: January 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

101 Total Publications

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma.
An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma.
Journal: bioRxiv : the preprint server for biology
Published: July 19, 2024
Similar Doctors
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Gun H. Lee
Dermatology
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Gun H. Lee
Dermatology

Permanente Medical Group Inc

3555 Whipple Rd, 
Union City, CA 
 (12.8 mi)
510-675-3080
Experience:
5+ years
Languages Spoken:
English

Gun Lee is a Dermatologist in Union City, California. Dr. Lee has been practicing medicine for over 5 years and is rated as an Experienced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. His top areas of expertise are Lymphomatoid Papulosis, Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Epidermolysis Bullosa.

Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Lisa D. Hisaw
Dermatology
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Lisa D. Hisaw
Dermatology
710 Lawrence Expy, Gme Dept. 384, 
Santa Clara, CA 
 (11.9 mi)
408-851-4480
Languages Spoken:
English

Lisa Hisaw is a Dermatologist in Santa Clara, California. Dr. Hisaw and is rated as an Advanced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Pityriasis Rubra Pilaris, Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Bullae.

Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Albert S. Chiou
Dermatology
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Albert S. Chiou
Dermatology

Stanford Dermatology Clinic In Livermore

1133 East Stanley Boulevard, Suite 111, 
Livermore, CA 
 (33.4 mi)
650-723-6316
Experience:
12+ years
Languages Spoken:
English
Offers Telehealth

Albert Chiou is a Dermatologist in Livermore, California. Dr. Chiou has been practicing medicine for over 12 years and is rated as an Advanced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. His top areas of expertise are Epidermolysis Bullosa, Atopic Dermatitis, Rosacea, and Actinic Keratosis.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile